Physician profile
Kimberly Smith
NPI 1508411562
$2,710.32
in general payments reported to CMS, 2019-2025
26 companies · $560 in 2025
The $560 reported for 2025 was more than what 76% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $485 · 2022: $409 · 2023: $648 · 2024: $608 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $928.68 | 2021-2025 | |
| Novo Nordisk INC | $229.93 | 2021-2025 | Ozempic, Rybelsus |
| Amgen INC. | $198.82 | 2021-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $170.96 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novartis Pharmaceuticals Corporation | $130.07 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $124.22 | 2022-2025 | |
| Cti Biopharma Corp. | $108.71 | 2023 | Vonjo |
| Glaxosmithkline, LLC. | $105.99 | 2021-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $104.39 | 2022-2025 | Farxiga, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $97.65 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $51.85 | 2022-2024 | Gvoke Hypopen |
| Sitesaver INC. | $50.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $48.64 | 2024-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $46.82 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| E.R. Squibb & Sons, L.L.C. | $42.23 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $37.68 | 2025 | Caplyta |
| Astellas Pharma US INC | $31.28 | 2021 | |
| Medtronic, INC. | $30.79 | 2024-2025 | Minimed 780g |
| Exact Sciences Corporation | $30.28 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $29.21 | 2021-2023 | |
| Pfizer INC. | $26.37 | 2021-2024 | |
| Esperion Therapeutics, INC. | $24.07 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $19.01 | 2021 | |
| Virtus Pharmaceuticals LLC | $17.78 | 2024 | Levorphanol Tartrate |
| Dexcom, INC. | $13.39 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.